PMID- 30458787
OWN - NLM
STAT- MEDLINE
DCOM- 20190423
LR  - 20190423
IS  - 1476-4598 (Electronic)
IS  - 1476-4598 (Linking)
VI  - 17
IP  - 1
DP  - 2018 Nov 20
TI  - LncRNA MIR31HG targets HIF1A and P21 to facilitate head and neck cancer cell 
      proliferation and tumorigenesis by promoting cell-cycle progression.
PG  - 162
LID - 10.1186/s12943-018-0916-8 [doi]
LID - 162
AB  - LncRNAs are involved in the initiation and progression of cancer. However, the 
      molecular mechanism and diverse clinical prognosis of MIR31HG in head and neck 
      squamous cell carcinoma (HNSCC) are still unclear. Our previous microarray 
      analysis showed that lncRNA MIR31HG interacted with HIF1A may play an oncogenic 
      role in laryngeal squamous cell cancer (LSCC). To determine whether lncRNA 
      MIR31HG served as a poor prognosis factor and targeted HIF1A to facilitate cell 
      proliferation and tumorigenesis in human HNSCC, we found MIR31HG and HIF1A were 
      overexpressed in LSCC, MIR31HG overexpression or co-expression of HIF1A-positive 
      and p21-negative could serve as a poor prognostic factor for LSCC patients. We 
      further confirmed that MIR31HG promoted cell proliferation, cell cycle 
      progression, and inhibited cell apoptosis in vitro and in vivo. The ingenuity 
      pathway analysis and Western blot indicated that MIR31HG regulated cell cycle 
      progression via HIF1A and p21 in HNSCC. The current results provide evidences for 
      the role of MIR31HG in promoting HNSCC progression and identify MIR31HG as a 
      prognostic biomarker and putative therapeutic target in HNSCC.
FAU - Wang, Ru
AU  - Wang R
AD  - Department of Otolaryngology Head and Neck Surgery, Beijing Tongren Hospital, 
      Capital Medical University, Beijing, 100730, China.
AD  - Key Laboratory of Otolaryngology Head and Neck Surgery (Ministry of Education of 
      China), Beijing Institute of Otolaryngology, Beijing, 100005, China.
FAU - Ma, Zhihong
AU  - Ma Z
AD  - Beijing Key Laboratory of Head and Neck Molecular Diagnostic Pathology, Beijing, 
      100730, China.
AD  - Department of Otolaryngology, Chengde Central Hospital, Chengde, 067000, Hebei, 
      China.
FAU - Feng, Ling
AU  - Feng L
AD  - Department of Otolaryngology Head and Neck Surgery, Beijing Tongren Hospital, 
      Capital Medical University, Beijing, 100730, China.
AD  - Key Laboratory of Otolaryngology Head and Neck Surgery (Ministry of Education of 
      China), Beijing Institute of Otolaryngology, Beijing, 100005, China.
FAU - Yang, Yifan
AU  - Yang Y
AD  - Department of Otolaryngology Head and Neck Surgery, Beijing Tongren Hospital, 
      Capital Medical University, Beijing, 100730, China.
AD  - Key Laboratory of Otolaryngology Head and Neck Surgery (Ministry of Education of 
      China), Beijing Institute of Otolaryngology, Beijing, 100005, China.
FAU - Tan, Chen
AU  - Tan C
AD  - Department of Otolaryngology Head and Neck Surgery, Beijing Tongren Hospital, 
      Capital Medical University, Beijing, 100730, China.
AD  - Key Laboratory of Otolaryngology Head and Neck Surgery (Ministry of Education of 
      China), Beijing Institute of Otolaryngology, Beijing, 100005, China.
FAU - Shi, Qian
AU  - Shi Q
AD  - Department of Otolaryngology Head and Neck Surgery, Beijing Tongren Hospital, 
      Capital Medical University, Beijing, 100730, China.
AD  - Key Laboratory of Otolaryngology Head and Neck Surgery (Ministry of Education of 
      China), Beijing Institute of Otolaryngology, Beijing, 100005, China.
FAU - Lian, Meng
AU  - Lian M
AD  - Department of Otolaryngology Head and Neck Surgery, Beijing Tongren Hospital, 
      Capital Medical University, Beijing, 100730, China.
AD  - Key Laboratory of Otolaryngology Head and Neck Surgery (Ministry of Education of 
      China), Beijing Institute of Otolaryngology, Beijing, 100005, China.
FAU - He, Shizhi
AU  - He S
AD  - Department of Otolaryngology Head and Neck Surgery, Beijing Tongren Hospital, 
      Capital Medical University, Beijing, 100730, China.
AD  - Key Laboratory of Otolaryngology Head and Neck Surgery (Ministry of Education of 
      China), Beijing Institute of Otolaryngology, Beijing, 100005, China.
FAU - Ma, Hongzhi
AU  - Ma H
AD  - Department of Otolaryngology Head and Neck Surgery, Beijing Tongren Hospital, 
      Capital Medical University, Beijing, 100730, China.
AD  - Key Laboratory of Otolaryngology Head and Neck Surgery (Ministry of Education of 
      China), Beijing Institute of Otolaryngology, Beijing, 100005, China.
FAU - Fang, Jugao
AU  - Fang J
AD  - Department of Otolaryngology Head and Neck Surgery, Beijing Tongren Hospital, 
      Capital Medical University, Beijing, 100730, China. fangjg19651110@163.com.
AD  - Key Laboratory of Otolaryngology Head and Neck Surgery (Ministry of Education of 
      China), Beijing Institute of Otolaryngology, Beijing, 100005, China. 
      fangjg19651110@163.com.
AD  - Beijing Key Laboratory of Head and Neck Molecular Diagnostic Pathology, Beijing, 
      100730, China. fangjg19651110@163.com.
LA  - eng
PT  - Letter
PT  - Research Support, Non-U.S. Gov't
DEP - 20181120
PL  - England
TA  - Mol Cancer
JT  - Molecular cancer
JID - 101147698
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (Cyclin-Dependent Kinase Inhibitor p21)
RN  - 0 (Hypoxia-Inducible Factor 1, alpha Subunit)
RN  - 0 (RNA, Long Noncoding)
RN  - 0 (long noncoding RNA MIR31HG, human)
SB  - IM
MH  - Biomarkers, Tumor
MH  - Cell Cycle/*genetics
MH  - Cell Line, Tumor
MH  - Cell Proliferation
MH  - Cell Transformation, Neoplastic/*genetics
MH  - Cyclin-Dependent Kinase Inhibitor p21/*genetics
MH  - *Gene Expression Regulation, Neoplastic
MH  - Head and Neck Neoplasms/*genetics/mortality/pathology
MH  - Humans
MH  - Hypoxia-Inducible Factor 1, alpha Subunit/*genetics
MH  - Prognosis
MH  - *RNA Interference
MH  - RNA, Long Noncoding/*genetics
PMC - PMC6247607
OTO - NOTNLM
OT  - Cell cycle
OT  - HIF1A
OT  - HNSCC
OT  - Prognosis
OT  - lncRNA MIR31HG
OT  - p21
COIS- ETHICS APPROVAL AND CONSENT TO PARTICIPATE: The study protocol was reviewed and 
      approved by the Ethics Committee of Beijing Tongren Hospital, Capital Medical 
      University. The study was undertaken in accordance with the ethical standards of 
      the World Medical Association Declaration of Helsinki. The experimental animal 
      protocols complied with IACUC (Institutional Animal Care and Use Committee) 
      regulations and were approved by the Ethics Committee of Beijing Tongren 
      Hospital, Capital Medical University, Beijing, China. CONSENT FOR PUBLICATION: 
      All authors have read and approved the final manuscript, and consent to the 
      publication of the manuscript in Molecular Cancer. COMPETING INTERESTS: The 
      authors declare that they have no competing interests. PUBLISHER'S NOTE: Springer 
      Nature remains neutral with regard to jurisdictional claims in published maps and 
      institutional affiliations.
EDAT- 2018/11/22 06:00
MHDA- 2019/04/24 06:00
PMCR- 2018/11/20
CRDT- 2018/11/22 06:00
PHST- 2018/07/29 00:00 [received]
PHST- 2018/11/12 00:00 [accepted]
PHST- 2018/11/22 06:00 [entrez]
PHST- 2018/11/22 06:00 [pubmed]
PHST- 2019/04/24 06:00 [medline]
PHST- 2018/11/20 00:00 [pmc-release]
AID - 10.1186/s12943-018-0916-8 [pii]
AID - 916 [pii]
AID - 10.1186/s12943-018-0916-8 [doi]
PST - epublish
SO  - Mol Cancer. 2018 Nov 20;17(1):162. doi: 10.1186/s12943-018-0916-8.